Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Bart Benraad"'
1
PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia
Autor: Jan Telman, Jan Beute, Zuzana Diamant, Pieter Boermans, Alex KleinJan, Bart Benraad
Publikováno v: Experimental Lung Research
Experimental lung research, 47(3), 149-160. Taylor & Francis Group
Experimental Lung Research, 47(3), 149-160. Informa Healthcare
article-version (VoR) Version of Record
BackgroundStandard care in severe SARS-CoV-2 pneumonia complicated by severe dyspnea and respiratory failure, consists of symptom reduction, ultimately supported by mechanical ventilation. Patients with severe SARS-CoV-2, a prominent feature of COVID
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7064ea7e293f8e349d4e8f988c28a2c
https://doi.org/10.1080/01902148.2021.1881189
Zobrazit plný text záznamu
2
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
Autor: Aatke van den Maas, Piet L. C. M. van Riel, Alfons A den Broeder, H Bart Benraad, Bart J F van den Bemt, Frank H J van den Hoogen, Gertjan Wolbink, Yechiel A. Hekster
Publikováno v: British Journal of Clinical Pharmacology. 76:939-945
AIM: Early prediction of (non-)response to infliximab therapy can improve therapeutic benefit by avoiding unnecessary periods of high disease activity during ineffective therapy. This prospective cohort study therefore aimed to study the predictive v
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d65c4e619e785993c1b9d4a80973d840
https://doi.org/10.1111/bcp.12142
Zobrazit plný text záznamu
3
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
Autor: G.F. Snijders, Bart Benraad, F.H.J. van den Hoogen, B. van den Bemt, Yechiel A. Hekster, A.A. den Broeder, P.L.C.M. van Riel, Gertjan Wolbink
Publikováno v: Annals of the Rheumatic Diseases, 67, 1697-701
Annals of the Rheumatic Diseases, 67, 12, pp. 1697-701
Contains fulltext : 70888.pdf (Publisher’s version ) (Closed access) OBJECTIVES: In clinical trials only a small subset of patients with rheumatoid arthritis (RA) benefits from higher than standard dose of infliximab (>3 mg/kg/8 weeks). However, do
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2644e27c9ce6f2df419bcdf3c860b543
https://doi.org/10.1136/ard.2007.083683
Zobrazit plný text záznamu
4
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
Autor: Bart J F, van den Bemt, Alfons A, den Broeder, Gert-Jan, Wolbink, Aatke, van den Maas, Yechiel A, Hekster, Piet L C M, van Riel, H Bart, Benraad, Frank H J, van den Hoogen
Publikováno v: British journal of clinical pharmacology. 76(6)
Early prediction of (non-)response to infliximab therapy can improve therapeutic benefit by avoiding unnecessary periods of high disease activity during ineffective therapy. This prospective cohort study therefore aimed to study the predictive value
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c24d671a29031b3d45717f7abb7f3074
https://pubmed.ncbi.nlm.nih.gov/23601129
Zobrazit plný text záznamu
5
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
Autor: Bart Benraad, Bart J F van den Bemt, Alfons A den Broeder, Yechiel A. Hekster, Gertjan Wolbink, Piet L. C. M. van Riel, Frank H J van den Hoogen
Publikováno v: BMC Musculoskeletal Disorders, Vol 12, Iss 1, p 12 (2011)
BMC Musculoskeletal Disorders
BMC Musculoskeletal Disorders, 12, 12-12
BMC Musculoskeletal Disorders, 12, pp. 12-12
Contains fulltext : 97636.pdf (Publisher’s version ) (Open Access) BACKGROUND: This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to as
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7763bc574910c66898701653b7c522
https://doi.org/10.1186/1471-2474-12-12
Zobrazit plný text záznamu
6
Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis
Autor: Bart Benraad, P.L.C.M. van Riel, B. van den Bemt, W.G.J.M. van Lankveld, A.A. den Broeder, F.H.J. van den Hoogen, Yechiel A. Hekster
Publikováno v: Scandinavian Journal of Rheumatology, 40, 192-6
Scandinavian Journal of Rheumatology, 40, 3, pp. 192-6
Item does not contain fulltext OBJECTIVES: We have developed an instrument that provides the physician structured information about medication use and patients' (non-)adherence. This study aimed to determine the effectiveness of this instrument on ad
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ed13730aac043ef6d9f80be7d4ffad
https://pubmed.ncbi.nlm.nih.gov/20977385
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje